InvestorsHub Logo
Followers 0
Posts 85
Boards Moderated 0
Alias Born 01/29/2008

Re: Zenos Arrow post# 6888

Wednesday, 05/19/2010 2:40:20 AM

Wednesday, May 19, 2010 2:40:20 AM

Post# of 18410
I said a "A reasonable place to start for estimating the bare minimum value of the HDVY urine test..." That is where I started. I tossed that out because I was interested in knowing how many here, (who have owned the stock for seven years) had gone even that far. I like to make money, so I have learned a lot since then.

Now when you vaguely referred to gene expression tests, were you talking about the PCA3 test? If so, is it your understanding that Medicare reimbursement for that test includes it's use as a screening test for PC? The urologists I have consulted tell me that the current indication is for evaluation following a negative biopsy. It seems that PCA3 as currently applied may not be as good as PSA for screening. Its sensitivity for detection of PC has been shown in studies to be in the 65% to 70% range, which is slightly lower than PSA's sensitivity. But for specifity, PCA3 is in the 75% to 80% range, which is much better than PSA. And that is all good news for us. Right Zeno?

Zeno, do you know what the Medicare criteria for PCA3 reimbursement is, and the amount? I do, but I don't want to spoil these guys by spoon feeding them everything.

Also, you seemed to concur that the 'royalties' that HDVY is expected to receive are going to be '2.45%'. That is incorrect.